Dr. Talar Ahmad Ahmad Merza Mohammad

Prof. Dr. Talar Ahmad Ahmad Merza Mohammad

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
AMAmirhossein Mardi
Amirhossein Mardi
ASAnastasia V. Shirokova
Anastasia V. Shirokova
RMRebar N. Mohammed
Rebar N. Mohammed
AKAli Keshavarz
Ali Keshavarz
AZAngelina O. Zekiy
Angelina O. Zekiy
MAMorteza Akbari
Morteza Akbari
Chimeric antigen receptor (CAR) T-cell therapy is a promising and rapidly expanding therapeutic option for a wide range of human malignancies. Despite the ongoing progress of CAR T-cell therapy in hematologic malignancies, the application of this therapeutic strategy in solid tumors has encountered several challenges due to antigen heterogeneity, suboptimal CAR T-cell trafficking, and the immunosuppressive features of the tumor microenvironment (TME). Oncolytic virotherapy is a novel cancer therapy that employs competent or genetically modified oncolytic viruses (OVs) to preferentially proliferate in tumor cells. OVs in combination with CAR T-cells are promising candidates for overcoming the current drawbacks of CAR T-cell application in tumors through triggering immunogenic cell death (ICD) in cancer cells. ICD is a type of cellular death in which danger-associated molecular patterns (DAMPs) and tumor-specific antigens are released, leading to the stimulation of potent anti-cancer immunity. In the present review, we discuss the biological causes of ICD, different types of ICD, and the synergistic combination of OVs and CAR T-cells to reach potent tumor-specific immunity.

22 July 2023 in Cellular Immunology
Verified
Journal Article
Closed access
QBQoyama Noel Baito
Qoyama Noel Baito
HJHalmat M. Jaafar
Halmat M. Jaafar
DMDr. Talar Ahmad Ahmad Merza Mohammad
Dr. Talar Ahmad Ahmad Merza Mohammad

6 May 2024 in Pharmacopsychiatry
Verified
Journal Article
Closed access
PDF file
DMDr. Talar Ahmad Ahmad Merza Mohammad
Dr. Talar Ahmad Ahmad Merza Mohammad
DSDyar M. Salman
Dyar M. Salman
HJHalmat M. Jaafar
Halmat M. Jaafar
Background Evidence indicates an association between immune dysregulation and major depressive disorder (MDD). Pentoxifylline (PTX), a phosphodiesterase inhibitor, has been shown to reduce pro-inflammatory activities. The aim of this study was to evaluate changes in depressive symptoms and pro-inflammatory markers after administration of PTX as an adjunctive agent to citalopram in patients with MDD. Methods One hundred patients were randomly assigned to either citalopram (20 mg/day) plus placebo (twice daily) (n=50) or citalopram (20 mg/day) plus PTX (400 mg) (twice daily) (n=50). The Hamilton Depression Rating Scale-17 (HAM-D-17) scores at baseline, weeks 2, 4, 6, 8, 10, and 12 and serum levels of interleukin1-β (IL-1-β), tumor necrosis factor-α, C-reactive protein, IL-6, serotonin, IL-10, and brain-derived neurotrophic factor (BDNF) at baseline and week 12 were evaluated. Results HAM-D-17 score in the PTX group significantly reduced in comparison to the control group after weeks 4, 6, 8,10, and 12 ((LSMD): − 2.193, p=0.021; − 2.597, p=0.036; − 2.916, p=0.019; − 4.336, p=0.005; and − 4.087, p=0.008, respectively). Patients who received PTX had a better response (83%) and remission rate (79%) compared to the placebo group (49% and 40%, p=0.006 and p=0.01, respectively). Moreover, the reduction in serum concentrations of pro-inflammatory factors and increase in serotonin and BDNF in the PTX group was significantly greater than in the placebo group (p<0.001). Conclusion These findings support the safety and efficacy of PTX as an adjunctive antidepressant agent with anti-inflammatory effects in patients with MDD.

1 January 2022 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JXJi Xu
Ji Xu
SFSahar Mashayekhi Firouz
Sahar Mashayekhi Firouz
MFMina Farrokhian
Mina Farrokhian
SGShadi Ghoreishizadeh
Shadi Ghoreishizadeh
DMDr. Talar Ahmad Ahmad Merza Mohammad
Dr. Talar Ahmad Ahmad Merza Mohammad
ASAli Sadeghian Shahi
Ali Sadeghian Shahi

12 June 2023 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
MAMaysoon Al‐Haideri
Maysoon Al‐Haideri
DMDr. Talar Ahmad Ahmad Merza Mohammad
Dr. Talar Ahmad Ahmad Merza Mohammad
SDShahram Darvishzadehdeldari
Shahram Darvishzadehdeldari
ZKZahra Karbasi
Zahra Karbasi
MAMina Alimohammadi
Mina Alimohammadi
RAReza Akhavan‐Sigari
Reza Akhavan‐Sigari

15 March 2024 in Indian Journal of Clinical Biochemistry
Verified
Journal Article
Closed access
PDF file
DMDr. Talar Ahmad Ahmad Merza Mohammad
Dr. Talar Ahmad Ahmad Merza Mohammad
HJHalmat M. Jaafar
Halmat M. Jaafar
AMAvin Mohammad Arif Maroof
Avin Mohammad Arif Maroof